Ascend Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Ascend Capital’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2,133	Closed	-$770K	–	177
2015 Q2	$1.35M	Sell	2,133 -248	-10%	-$132K	0.04%	133
2015 Q1	$1.23M	Buy	+2,381	New	+$1.2M	0.04%	147

Other funds holding VIRX

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ascend Capital's VIRX Position: Q3 2015 in Review

Ascend Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 2,133 shares — an estimated $770K sold.

Ascend Capital first reported a position in VIRX in Q1 2015 and held it in 2 quarters. The position peaked at $1.35M in Q2 2015. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

Ascend Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
Ascend Capital sold 2,133 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $770K.
Ascend Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2015 and held it in 2 quarters.
Ascend Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $1.35M in Q2 2015.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Ascend Capital's 13F filing for Q3 2015, filed 13 Nov 2015.